Abstract

Omicron variant is circulating in the presence of a globally acquired immunity unlike the ancestral SARS-CoV-2 isolate. Herein, we investigated the normalized viral load dynamics and viral culture status in 44 fully vaccinated healthcare workers (HCWs) infected with the Omicron BA.1 variant. Viral load dynamics of 38 unvaccinated HCWs infected with the 20A variant during the first pandemic wave was also studied. We then explored the impact of Omicron infection on pre-existing immunity assessing anti-RBD IgG levels, neutralizing antibody titres against 19A, Delta and Omicron isolates, as well as IFN-γ release following cell stimulation with SARS-CoV-2 peptides. We reported that two weeks after diagnosis a greater proportion of HCWs infected with 20A (78.9%, 15/19) than with Omicron BA.1 (44.7%, 17/38; p = 0.02) were still positive by RT-qPCR. We found that Omicron breakthrough infections led to an overall enhancement of vaccine-induced humoral and cellular immunity as soon as a median [interquartile range] of 8 [7–9] days post symptom onset. Among samples with similar high viral loads, non-culturable samples exhibited higher neutralizing antibody titres and anti-RBD IgG levels than culturable samples. Additionally, Omicron infection led to an enhancement of antibodies neutralization capacity against other SARS-CoV-2 isolates. Taken together, the results suggest that Omicron BA.1 vaccine breakthrough infection is associated with a faster viral clearance than that of the ancestral SARS-CoV-2, in addition this new variant leads to a rapid enhancement of the humoral response against multiple SARS-CoV-2 variants, and of the cellular response.

Details

Title
Dynamics of viral shedding during ancestral or Omicron BA.1 SARS-CoV-2 infection and enhancement of pre-existing immunity during breakthrough infections
Author
Saade, Carla 1   VIAFID ORCID Logo  ; Brengel-Pesce, Karen 2 ; Gaymard, Alexandre 3 ; Mary-Anne Trabaud 4   VIAFID ORCID Logo  ; Destras, Gregory 5 ; Guy, Oriol 2 ; Cheynet, Valérie 2 ; Debombourg, Marion 2 ; Mokdad, Bouchra 2 ; Billaud, Geneviève 4 ; Oblette, Antoine 6 ; Créhalet, Hervé 7 ; Giannoli, Jean-Marc 8 ; Garrigou, Christine 4 ; Generenaz, Laurence 2 ; Compagnon, Christelle 2 ; Boibieux, André 9 ; Bruno, Lina 5   VIAFID ORCID Logo  ; Morfin, Florence 5   VIAFID ORCID Logo  ; Pozzetto, Bruno 10 ; Josset, Laurence 5   VIAFID ORCID Logo  ; Sophie Trouillet Assant 11   VIAFID ORCID Logo  ; Bal, Antonin 5   VIAFID ORCID Logo 

 CIRI, Centre International de Recherche en Infectiologie, Team VirPath, Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, Lyon, France; Joint Research Unit Civils Hospices of Lyon-bioMérieux, Civils Hospices of Lyon, Lyon Sud Hospital, Pierre-Bénite, France 
 Joint Research Unit Civils Hospices of Lyon-bioMérieux, Civils Hospices of Lyon, Lyon Sud Hospital, Pierre-Bénite, France 
 CIRI, Centre International de Recherche en Infectiologie, Team VirPath, Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, Lyon, France; Laboratoire de Virologie, Institut des Agents Infectieux, Laboratoire associé au Centre National de Référence des virus des infections respiratoires, Hospices Civils de Lyon, Lyon, France 
 Laboratoire de Virologie, Institut des Agents Infectieux, Laboratoire associé au Centre National de Référence des virus des infections respiratoires, Hospices Civils de Lyon, Lyon, France 
 CIRI, Centre International de Recherche en Infectiologie, Team VirPath, Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, Lyon, France; Laboratoire de Virologie, Institut des Agents Infectieux, Laboratoire associé au Centre National de Référence des virus des infections respiratoires, Hospices Civils de Lyon, Lyon, France; GenEPII sequencing platform, Institut des Agents Infectieux, Hospices Civils de Lyon, Lyon, France 
 Laboratoire de Virologie, Institut des Agents Infectieux, Laboratoire associé au Centre National de Référence des virus des infections respiratoires, Hospices Civils de Lyon, Lyon, France; GenEPII sequencing platform, Institut des Agents Infectieux, Hospices Civils de Lyon, Lyon, France 
 Mirialis - Biogroup Auvergne Rhône alpes, Cluses, France 
 Dyomédéa-BIOGROUP – Plateau technique de la Sauvegarde, Lyon, France 
 Infectious and Tropical Diseases Unit, Hospices Civil de Lyon, Lyon, France 
10  Team GIMAP, CIRI—Centre International de Recherche en Infectiologie, Université Jean Monnet de Saint-Etienne, Université Claude Bernard Lyon 1, Inserm, U1111, CNRS, Saint-Etienne, France; Laboratoire des Agents Infectieux, Centre Hospitalier Universitaire de Saint-Étienne, Saint-Etienne, France 
11  CIRI, Centre International de Recherche en Infectiologie, Team VirPath, Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, Lyon, France; Joint Research Unit Civils Hospices of Lyon-bioMérieux, Civils Hospices of Lyon, Lyon Sud Hospital, Pierre-Bénite, France; Laboratoire de Virologie, Institut des Agents Infectieux, Laboratoire associé au Centre National de Référence des virus des infections respiratoires, Hospices Civils de Lyon, Lyon, France 
Pages
2423-2432
Publication year
2022
Publication date
Dec 2022
Publisher
Taylor & Francis Ltd.
e-ISSN
22221751
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2748038568
Copyright
© 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group, on behalf of Shanghai Shangyixun Cultural Communication Co., Ltd. This work is licensed under the Creative Commons Attribution License http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.